Diabetes Pharmacotherapy: A Medicinal Chemistry Perspective on Conventional, Emerging, and Plant-derived Antidiabetic Agents.
文献摘要
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia, arising from defective insulin secretion, impaired insulin action, or both. It represents a rapidly growing global health crisis, currently affecting over 537 million adults worldwide, with devastating microvascular and macrovascular complications including nephropathy, retinopathy, neuropathy, and cardiovascular disease risk. Current pharmacotherapy encompasses diverse drug classes targeting distinct pathophysiological mechanisms. Sulfonylureas and meglitinides stimulate insulin secretion, whereas biguanides suppress hepatic gluconeogenesis and activate AMPK. The thiazolidinediones enhance peripheral insulin sensitivity via PPAR-γ activation. The DPP-4 inhibitors and GLP-1 receptor agonists potentiate the incretin axis, whereas the SGLT-2 inhibitors promote renal glucose excretion. Amylin analogues modulate postprandial glucagon secretion. Beyond glycemic control, significant cardiovascular outcome trials, including EMPA-REG OUTCOME, DAPA-HF, DELIVER, and EMPEROR-Reduced, have established that certain agents confer significant cardio-renal protective benefits independent of their glucose-lowering effects. This review additionally surveys emerging antidiabetic compounds under clinical evaluation, including dual and triple incretin receptor agonists. The medicinal chemistry and key synthetic pathways of representative antidiabetic drugs are discussed to bridge pharmacology with chemical design, highlighting structure-activity relationships. Plant-derived antidiabetic agents are critically evaluated with emphasis laid on clinical evidence, bioavailability limitations, and regulatory considerations. A systematic literature search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and ClinicalTrials.gov, prioritizing publications from 2019 to 2025. Future directions, including AI-assisted drug discovery, pharmacogenomics, and β-cell regeneration strategies, are also discussed.